Literature DB >> 21983950

Innate immune environment in ileal pouch mucosa: α5 defensin up-regulation as predictor of chronic/relapsing pouchitis.

Marco Scarpa1, Alessia Grillo, Melania Scarpa, Paola Brun, Carlo Castoro, Anna Pozza, Donatella Cavallo, Diego Faggian, Cesare Ruffolo, Renata D'Incà, Romeo Bardini, Ignazio Castagliuolo, Imerio Angriman.   

Abstract

Defensins are small cationic peptides with antibacterial activity expressed in Paneth cells (α-defensins) or generally in intestinal epithelial cells (β-defensins) that have a profound effect on gut microbiota. Chronic pouchitis, which occurs in 5% of patients after restorative proctocolectomy and can cause pouch failure, is associated to a significant increase of Clostridiaceae spp. The aim of this study was to gain further insight in the pathogenesis of pouch dysbiosis by exploring defensin expression. Thirty-two consecutive patients coming for follow-up endoscopy were recruited. On pouch biopsies, we cultured bacteria adherent to the mucosa and determined α- and β-defensins and toll-like receptor-4 and -2 mRNA by quantitative real-time RT-PCR. Serum and mucosal levels of IL-1β, IL-6 and TNF-α were measured with immunometric assays. Faecal lactoferrin was analysed by quantitative ELISA. After a median follow-up of 23 (IQR 20-24) months, the patients were contacted for a reassessment of current and past disease activity. During the follow-up, chronic/relapsing pouchitis was diagnosed in six patients. The mucosal level of α-5 and α-6 defensins correlated with chronic/relapsing pouchitis onset (τ = 0.30, p = 0.034 and τ = 0.28, p = 0.053, respectively). High levels of α-5 defensin resulted to be predictive of chronic/relapsing pouchitis [AUC = 74% (95% CI = 53-89%), p = 0.052]. Patients with high levels of α-5 and α-6 defensins had earlier pouchitis relapses (p = 0.009 and p = 0.034, respectively). High levels of α-5 defensin were associated to a significant risk of chronic/relapsing pouchitis [OR = 10.6 (95% CI = 1.2-97.6), p = 0.027]. At multivariate analysis, the mucosal levels of α-5 defensin and the number of CFU of mucosa-associated Clostridiaceae spp resulted to be independent predictors of chronic/relapsing pouchitis [β = 0.46 (0.18), p = 0.024 and β = 0.44 (0.18), p = 0.027, respectively]. In conclusion, chronic/relapsing pouchitis is associated to increased expression of mucosal HD-5 and to increased antimicrobial activity against Escherichia coli. In patients with chronic/relapsing pouchitis, HD-5 and TLR-4 over-expression is likely to create a hostile environment against Enterobacteriaceae, thus favouring Clostridiaceae spp by decreasing competing bacteria families.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983950     DOI: 10.1007/s11605-011-1720-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  51 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

Authors:  Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

3.  Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Anna Pozza; Filippo Navaglia; Renata D'Incà; Pranvera Hoxha; Giovanna Romanato; Lino Polese; Giacomo Carlo Sturniolo; Mario Plebani; Davide Francesco D'Amico; Imerio Angriman
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

4.  Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.

Authors:  R D Hurst; M Molinari; T P Chung; M Rubin; F Michelassi
Journal:  Arch Surg       Date:  1996-05

5.  ICSH recommendations for measurement of erythrocyte sedimentation rate. International Council for Standardization in Haematology (Expert Panel on Blood Rheology)

Authors: 
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

6.  TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis.

Authors:  Marco Scarpa; Alessia Grillo; Anna Pozza; Diego Faggian; Cesare Ruffolo; Melania Scarpa; Renata D'Incà; Mario Plebani; Giacomo Carlo Sturniolo; Ignazio Castagliuolo; Imerio Angriman
Journal:  J Surg Res       Date:  2011-05-05       Impact factor: 2.192

7.  Association between fecal hydrogen sulfide production and pouchitis.

Authors:  Hiroki Ohge; Julie K Furne; John Springfield; David A Rothenberger; Robert D Madoff; Michael D Levitt
Journal:  Dis Colon Rectum       Date:  2005-03       Impact factor: 4.585

8.  IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines.

Authors:  Dirk Haller; Maria P Russo; R Balfour Sartor; Christian Jobin
Journal:  J Biol Chem       Date:  2002-07-24       Impact factor: 5.157

9.  NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.

Authors:  J Wehkamp; J Harder; M Weichenthal; M Schwab; E Schäffeler; M Schlee; K R Herrlinger; A Stallmach; F Noack; P Fritz; J M Schröder; C L Bevins; K Fellermann; E F Stange
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

10.  The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.

Authors:  Jan Wehkamp; Guoxing Wang; Irmgard Kübler; Sabine Nuding; Alex Gregorieff; Anke Schnabel; Robert J Kays; Klaus Fellermann; Oliver Burk; Matthias Schwab; Hans Clevers; Charles L Bevins; Eduard F Stange
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

View more
  6 in total

Review 1.  Inflammatory bowel disease: an impaired barrier disease.

Authors:  Simon Jäger; Eduard F Stange; Jan Wehkamp
Journal:  Langenbecks Arch Surg       Date:  2012-11-18       Impact factor: 3.445

Review 2.  Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis.

Authors:  Imerio Angriman; Marco Scarpa; Ignazio Castagliuolo
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection.

Authors:  William A Eimer; Deepak Kumar Vijaya Kumar; Nanda Kumar Navalpur Shanmugam; Alex S Rodriguez; Teryn Mitchell; Kevin J Washicosky; Bence György; Xandra O Breakefield; Rudolph E Tanzi; Robert D Moir
Journal:  Neuron       Date:  2018-07-11       Impact factor: 17.173

4.  Validation of the Padova Prognostic Score for Colitis in Predicting Long-Term Outcome After Restorative Proctocolectomy.

Authors:  Imerio Angriman; Annaclaudia Colangelo; Claudia Mescoli; Matteo Fassan; Renata D'Incà; Edoardo Savarino; Salvatore Pucciarelli; Romeo Bardini; Cesare Ruffolo; Marco Scarpa
Journal:  Front Surg       Date:  2022-07-25

5.  Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis.

Authors:  Ming Li; Pin Liang; Zhenzhen Li; Ying Wang; Guobin Zhang; Hongwei Gao; Shu Wen; Li Tang
Journal:  Front Microbiol       Date:  2015-07-07       Impact factor: 5.640

6.  Upregulated Expression of Intestinal Antimicrobial Peptide HD5 Associated with Renal Function in IgA Nephropathy.

Authors:  Shaozhen Feng; Zhong Zhong; Jinjin Fan; Xiaoyan Li; Dianchun Shi; Lanping Jiang
Journal:  Dis Markers       Date:  2020-02-05       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.